Navigation Links
Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
Date:12/14/2010

CAMBRIDGE, Mass., Dec. 14, 2010 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced that it has initiated a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.  

The Phase 1 trial will evaluate ascending single doses of TRX518 in patients with malignant melanoma. The clinical trial will be conducted by leading cancer researchers at the Memorial Sloan-Kettering Cancer Center and is supported by research funding to Tolerx from the Cancer Research Institute and clinical trials management expertise from the Ludwig Institute for Cancer Research Ltd., through its Cancer Vaccine Acceleration Fund (CVAF).

"We are very enthusiastic about leading the clinical study of TRX518 and evaluating this innovative immunotherapy, which offers a new approach to help cancer patients," said Jedd Wolchok, MD, PhD, director of immunotherapy clinical trials at Memorial Sloan-Kettering Cancer Center.  "In collaboration with Tolerx and the leadership team at the CVAF, we have assisted with the unique aspects of immunotherapy trials in cancer, including patient enrollment criteria, dosing strategy, trial endpoints, and other considerations to ensure the highest standards and quality results for the TRX518 Phase 1 study."

This open label, non-randomized, ascending dose design will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending intravenous doses of TRX518 in up to 40 patients with advanced stage III and IV malignant melanoma.  The goal is to determine the maximum tolerated dose of TRX518 as patients are assessed over the 18-week core study period.  In future clinical programs, Tolerx plans to evaluate TRX518 f
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDFs 20th World Diabetes Congress
2. Tolerx Announces Amendment to Phase 3 DEFEND Protocol
3. Tolerx Expands Phase 3 DEFEND Trial of Otelixizumab in Europe
4. Laureate Announces Manufacturing Agreement with Tolerx
5. Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety
6. GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System
7. SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK
8. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
9. Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
10. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
11. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... OAK RIDGE, Tenn., July 24, 2014 -- A novel ... at the Department of Energy,s Oak Ridge National Laboratory ... known for its unusual physical and electrochemical properties. ... examined how oxygen affects the surface of a perovskite ... electronic behavior. The new avenue to understand surface behavior ...
(Date:7/24/2014)... sophisticated equipment, trained personnel, and detection dogs to ... attacks. A revolutionary new electronic chip with nano-sized ... much easier. , The groundbreaking nanotechnology-inspired sensor, devised ... ,s School of Chemistry and Center for Nanoscience ... Tracense, picks up the scent of explosives molecules ...
(Date:7/24/2014)... 2014 Research and Markets has ... Market 2014-2018" report to their offering.  ... is the in vitro growth of plant or animal ... and biopharmaceutical production. Cell culture is a crucial step ... and cell culture consumables are necessary for the in ...
(Date:7/24/2014)... Three companies from the angelMD network were ... Competition. Out of 700 competition entrants, Chiron Health, Litesprite, ... round. In this round twenty teams are invited to ... mentoring from thought-leaders and medical entrepreneurs from all over ... commitment to the Livestrong vision around the Big C ...
Breaking Biology Technology:ORNL study reveals new characteristics of complex oxide surfaces 2Nano-sized chip 'sniffs out' explosives far better than trained dogs 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... Wisconsin's U.S. Senate campaign, Republican Tim Michels ... little more than an inconsequential sideshow. Michels said he ... uses adult stem cells or cells from umbilical cordsbut ... cells. , ,Technology is going to move us away ...
... Madison, Wis. Wisconsin could lose its carefully established ... Midwest if more money is not channeled into academic and ... Download the report (5.4 MB PDF) This ... advisor to the governor on technological matters. The report, titled ...
... businesses TeraMedica scans new market opportunity: smaller hospitals ... Platypus plans office move next June Ink ... more mobile computing Schneider buys GPS to track ... , UW-Extension gets $95,000 to help small businesses ...
Cached Biology Technology:It's 99 percent certain: Research cannot rely on adult stem cells alone 2It's 99 percent certain: Research cannot rely on adult stem cells alone 3Economic report raises red flags on Wisconsin's future 2Economic report raises red flags on Wisconsin's future 3Tech Digest: whats moving in the Midwest 2Tech Digest: whats moving in the Midwest 3
(Date:7/27/2014)... Scientists have discovered a new species of mayfly in the ... of India. In fact, this is the first time that ... been collected in peninsular India. , The new species, called ... T. Soldan for his substantial contribution to the understanding of ... authors of a study that describes the new mayfly in ...
(Date:7/27/2014)... "big data," a single computer cannot always find the ... distributed across a cluster of computers that analyze a ... mine your web history to present you with targeted ... favorite book or movie. But big data is about ... monitoring brain activity are generating unprecedented quantities of information. ...
(Date:7/25/2014)... burn scars on this false-color image from the Terra satellite ... year,s rash of wildfires in Eastern Russia. The burn ... green background. The wildfires have broken across the remote ... in this false-color image from the MODIS instrument, it ... fires that continue. Two recent image features noted below show ...
Breaking Biology News(10 mins):New tools help neuroscientists analyze 'big data' 2New tools help neuroscientists analyze 'big data' 3New tools help neuroscientists analyze 'big data' 4New tools help neuroscientists analyze 'big data' 5
... by Dr. Ann F. Jacobson, associate professor in Kent ... may initially choose to postpone but ultimately undergo total ... patient education before and after the procedure. ... pre-and post operative experiences with total knee replacement surgery, ...
... release is available in Spanish . , A ... (USA) and Nakai (China), among others, have deciphered for the first ... to the cover of the last issue of the prestigious journal ... to the group of Molecular Genetics of the Department of ...
... fund four faculty research projects for spring 2008. ... a number of excellent proposals submitted in response ... for the program is administered by the OSU ... by royalties from OSU-licensed technologies. These funded projects ...
Cached Biology News:Research examines factors in delaying or declining total knee replacement surgery 2Scientists decipher fruit tree genome for the first time 2Scientists decipher fruit tree genome for the first time 3OSU technologies funded for development 2OSU technologies funded for development 3
... NaCl, 20mM MOPS, pH 7.5, 60mM ... EGTA, 10 Properites: For selective in ... chromatography, divalent cation activation plus trypsin ... Assurance: routinely evaluated by dephosphorylation of ...
Mouse monoclonal [6G11] to Cytohesin 1 + 2 ( Abpromise for all tested applications)....
HNF-1 Purified Anti-Mouse, Anti-Rat, Anti-Rabbit, Anti-Human clone 2, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Recombinant Porcine IL-1 alpha/IL-1F1, CF...
Biology Products: